The global cancer immunotherapy market is accounted for $45,471 million in 2015, and is estimated to reach $117,114 million by 2022, growing at a CAGR of 14.5% during the analysis period of 2016-2022. Cancer Immunotherapy is a method of cancer treatment that boosts the immune system in fighting cancer. This therapy is more advantageous than the traditional approach as it delivers long-term protection against cancer, has minimal side effects, and avails treatment to more cancer types. Immunotherapy works by guiding system toward cancer-specific targets, followed by activation of immune system to mobilize the target, and produces response that can eradicate cancer targeted cells. There are many factors, such as increase in incidence of cancer, rise in healthcare expenditure, increased access to medical insurance, and technological advancements in cancer treatment therapies that fuel the growth of the global cancer immunotherapy market. However, the factors such as lack of awareness about cancer immunotherapy are anticipated to inhibit the growth of the market. Also, the high product developmental cost is expected to impede the growth of the market.
The market is segmented based on technology, application, end-users, and geography. By technology, this market is categorized into monoclonal antibodies, cytokines & immunomodulators, and other technologies. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. By end-users, it is divided into hospitals, cancer research centers, and clinics. Geographically, it is studied across North America, Europe, Asia Pacific, and LAMEA.
KEY MARKET BENEFITS:
Comprehensive analysis of factors that drive and restrict the growth of the global cancer immunotherapy market is provided.
The projections in the market are made by studying the current market trends and future market potential for the period (2014-2022) in terms of value.
Extensive analysis by technology and application helps understand the various trends and prevailing opportunities in the respective market
Key market players within the global cancer immunotherapy market are profiled in the market and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the global cancer immunotherapy market.
Comprehensive analysis of all regions are provided that determines the prevailing opportunities in these geographies.
KEY MARKET SEGMENT:
By Technology
Monoclonal Antibodies
Cytokines & Immunomodulators
Others (Immune Checkpoint Inhibitors, Cell Therapy, and Oncolytic Virus Immunotherapy)
By Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head & Neck Cancer
Others (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)
By End-Users
Hospitals
Cancer Research Centres
Clinics
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Others
Asia Pacific
Japan
China
India
Others
LAMEA
Latin America
Middle East
Africa
List of players profiled in the report
F. Hoffmann-La Roche AG.
Advaxis Inc.
Merck & Co., Inc.
Eli Lilly and Company
Bristol-Myers Squibb Company
Pfizer Inc.
Novartis AG
Bayer AG
Immunomedics Inc.
Astrazeneca plc.
List of other players (These companies are not profiled in the report and same can be done on demand)
Seattle Genetics
Peregrine Pharmaceuticals
Viralytics Ltd.
Takeda Pharmaceutical Company Ltd.
Amgen Inc.